Liraglutide
A GLP-1 medication that mimics a natural gut hormone (97% similar to native GLP-1) and is the predecessor to semaglutide. FDA-approved for both type 2 diabetes (Victoza) and obesity (Saxenda). One of the most prescribed weight loss medications worldwide, with extensive long-term safety data including reduced risk of heart attack and stroke in diabetic patients.
Dosage
Weight loss: 3.0 mg subcutaneous daily. Diabetes: 1.2-1.8 mg daily
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (daily)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
Approximately 5-8% body weight reduction at 3.0 mg daily dose.
Blood Sugar Control
FDA-approved for both diabetes and obesity with extensive safety data.
Cardiovascular Protection
LEADER trial showed reduced major adverse cardiovascular events.
Mechanism of Action
Liraglutide is a GLP-1 receptor agonist with 97% amino acid homology to native human GLP-1(7-37), modified by a single amino acid substitution (Lys34Arg) and attachment of a C16 palmitoyl fatty acid chain to Lys26 via a glutamic acid spacer. This acylation is the key pharmacological modification — the C16 fatty acid chain non-covalently binds to serum albumin after injection, creating an albumin-bound depot that is slowly released, extending the half-life from 1-2 minutes (native GLP-1) to approximately 13 hours. The acylation also confers resistance to DPP-4 enzymatic degradation.
Liraglutide activates the GLP-1 receptor (GLP-1R), a Gs-coupled GPCR expressed in pancreatic beta cells, the hypothalamus, the gastrointestinal tract, and the cardiovascular system. In pancreatic beta cells, GLP-1R activation increases intracellular cAMP, which enhances glucose-stimulated insulin secretion (GSIS) through PKA and Epac2 (exchange protein activated by cAMP) signaling. Crucially, this insulin secretion is glucose-dependent — it only occurs when blood glucose is elevated, which greatly reduces the risk of hypoglycemia compared to insulin or sulfonylureas. GLP-1R activation also suppresses glucagon secretion from alpha cells (reducing hepatic glucose output), promotes beta cell proliferation, and inhibits beta cell apoptosis.
The weight loss mechanism operates primarily through hypothalamic GLP-1R activation. GLP-1 receptors in the arcuate nucleus and paraventricular nucleus reduce appetite by activating POMC/CART (anorexigenic) neurons and inhibiting NPY/AgRP (orexigenic) neurons. This produces a sustained reduction in hunger and food intake. In the GI tract, GLP-1R activation delays gastric emptying, prolonging postprandial satiety and slowing the rate of nutrient absorption. The combined effects on appetite reduction and gastric emptying produce clinically meaningful weight loss — approximately 5-8% of body weight in clinical trials at the 3.0 mg daily dose (Saxenda). The LEADER cardiovascular outcomes trial demonstrated that liraglutide also reduces major adverse cardiovascular events, likely through anti-inflammatory, anti-atherogenic, and cardioprotective effects of GLP-1R activation in vascular endothelium and cardiomyocytes.
Regulatory Status
FDA approved: Victoza (2010, diabetes), Saxenda (2014, weight management). EMA approved. Widely available globally. Prescription required.
Risks & Safety
Common
nausea (40%+ initially, typically resolves within 2-4 weeks), vomiting, diarrhea, constipation, injection site reactions, headache.
Serious
pancreatitis, gallbladder disease including gallstones, acute kidney injury from dehydration, thyroid C-cell tumors (boxed warning based on rodent studies).
Rare
anaphylaxis, angioedema, medullary thyroid carcinoma (theoretical). Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.
Compare Liraglutide With
Research Papers
30Published: February 8, 2026
AI Summary
Modifications like fatty-acid conjugation can extend peptide drug half-lives, enabling weekly dosing. The review explains how peptide pharmacokinetics scale across species and how to apply classic PK principles.
Published: February 4, 2026
AI Summary
GLP-1 agonists reduced sexual behavior in female rats and mice in drug- and species-specific ways, while increasing sociability in some tests. The results expand understanding of how these drugs affect reward-related behavior beyond metabolism.
Published: January 20, 2025
AI Summary
A pilot trial protocol was designed to test whether liraglutide improves depressive symptoms in overweight or obese adults with type 2 diabetes. The drug may address both blood sugar and mood in this high-burden group.
Published: December 4, 2026
AI Summary
GLP-1 agonists lowered kidney and heart events, death, and albuminuria in chronic kidney disease patients, mainly with diabetes, but increased nausea, vomiting, and diarrhea. The meta-analysis supports cardiorenal benefits despite GI side effects.
Published: February 2, 2026
AI Summary
Liraglutide reduced fatty infiltration and improved shoulder motion and muscle activity in rats with chronic rotator cuff tears. The findings suggest GLP-1 agonists could help limit muscle degeneration after tendon injury.
Published: February 3, 2026
AI Summary
A meta-analysis compared the safety and effectiveness of GLP-1 agonists for obesity in older versus younger adults. The work aims to guide use in the elderly.
Published: February 21, 2026
AI Summary
An algorithm-based framework was developed to measure and visualize blood flow and oxygen in the pancreas of diabetic mice. The approach could clarify how islet and exocrine tissue interact.
Published: February 1, 2026
AI Summary
Liraglutide improved blood vessel function in diabetic mice by restoring gut bacteria diversity and enriching SCFA-producing species. The results support a GLP-1–microbiome–vascular link in diabetes.
Published: February 1, 2026
AI Summary
Obesity management in psoriasis was reviewed, including lifestyle, GLP-1 agonists, tirzepatide, and surgery. The work offers guidance for dermatologists treating obese psoriasis patients.
Published: January 31, 2026
AI Summary
Zinc oxide particles with a compact spiky shape delivered inhaled liraglutide with about 60% bioavailability in rats, far above oral semaglutide. The approach could enable non-injectable peptide delivery.
Published: January 31, 2026
AI Summary
Liraglutide reduced brain injury in septic mice by limiting neuronal damage, glial activation, and mitochondrial dysfunction. The findings suggest GLP-1 agonists may help treat sepsis-related encephalopathy.
Published: January 30, 2026
AI Summary
GLP-1 agonists reduced weight and HbA1c in people with severe mental illness and were generally acceptable and tolerable. The meta-analysis supports their use in this population with cardiometabolic risk.
Published: January 27, 2026
AI Summary
Liraglutide and long-acting GIP and xenin analogues improved cognition and reduced amyloid in a mouse model of Alzheimer's. The results support exploring gut hormone analogues for neurodegenerative disease.
Published: January 27, 2026
AI Summary
Liraglutide, semaglutide, and tirzepatide were compared for obesity in non-diabetic patients, including efficacy, cost, and clinical use. The review summarizes approved incretin-based options for weight loss.
Published: May 13, 2026
AI Summary
Liraglutide in silica nanoparticles coated with a cell-penetrating peptide and hyaluronic acid was absorbed orally in diabetic rats, lowering blood sugar and weight comparably to injections. The approach could enable non-injectable peptide delivery.
Published: January 1, 2026
AI Summary
GLP-1 agonist use was evaluated in diabetic patients with prior major limb events. The work aims to identify effective glucose-lowering options for secondary prevention in this high-risk group.
Published: January 27, 2026
AI Summary
Liraglutide raised zinc levels and improved mitochondria in aged, insulin-resistant heart cells via casein kinase 2. The findings suggest a mechanism for its cardioprotective effects in metabolic disease.
Published: January 3, 2026
AI Summary
A meta-analysis of three trials found no clear cognitive benefit from liraglutide or exenatide in Alzheimer's or mild cognitive impairment. Current evidence does not support GLP-1 agonists for cognitive improvement in these conditions.
Published: January 11, 2026
AI Summary
GLP-1 agonists affect ovarian function via FOXO1, steroidogenesis, and BMP signaling, and may improve pregnancy rates in PCOS. The review integrates IVF data, ovarian biology, and molecular mechanisms.
Published: January 6, 2026
AI Summary
High-dose canagliflozin was linked to higher intestinal obstruction risk, while liraglutide was associated with lower risk. The network meta-analysis refines GI safety profiles for GLP-1 agonists and SGLT2 inhibitors.
Published: January 5, 2026
AI Summary
GLP-1 agonist use was linked to lower pancreatic cancer incidence in patients with chronic pancreatitis, including those with diabetes. The findings suggest a possible benefit in this high-risk group.
Published: January 23, 2026
AI Summary
Weekly liraglutide reduced thirst and interdialytic weight gain in a dialysis patient with refractory polydipsia. The case suggests GLP-1 agonists may help manage fluid overload in end-stage kidney disease.
Published: January 25, 2026
AI Summary
A meta-analysis examined the effect of GLP-1 agonists on heart rate in overweight or obese adults without diabetes. The work aims to clarify whether these drugs raise heart rate in this population.
Published: January 21, 2026
AI Summary
Liraglutide reduced microglial pyroptosis after spinal cord injury by restoring FANCC via the PI3K/Akt/TFEB pathway. The results support GLP-1 receptor activation as a potential treatment for secondary spinal cord injury.
Published: January 14, 2026
AI Summary
Liraglutide improved bone healing in a rat skull defect model when combined with various graft materials. The findings suggest GLP-1 agonists could support bone regeneration.
Published: January 31, 2026
AI Summary
Liraglutide, empagliflozin, and their combination reduced carotid thickness and amyloid-related markers more than insulin in diabetic patients. The combination produced the largest improvements in vascular markers.
Published: January 23, 2026
AI Summary
Exercise and GLP-1 agonist treatment were compared alone and combined for physical fitness after diet-induced weight loss in obese adults. The secondary analysis explores effects on fitness outcomes.
Published: January 22, 2026
AI Summary
A case of diabetic ketoacidosis after a large liraglutide overdose for weight loss is described. The report highlights risks of misuse and the need for clear prescribing and patient education.
Published: January 22, 2026
AI Summary
Evidence on GLP-1 agonist effects on muscle strength in older adults was summarized. Longer-term use may be linked to strength loss and sarcopenia, so monitoring and future trials in the elderly are needed.
Published: February 1, 2026
AI Summary
Liraglutide aggregation in prefilled syringes was driven by combined air–water and silicone oil–water interfacial stress. The findings inform design of peptide formulations to limit aggregation.
Frequently Asked Questions
What is Liraglutide?
A GLP-1 medication that mimics a natural gut hormone (97% similar to native GLP-1) and is the predecessor to semaglutide. FDA-approved for both type 2 diabetes (Victoza) and obesity (Saxenda). One of the most prescribed weight loss medications worldwide, with extensive long-term safety data including reduced risk of heart attack and stroke in diabetic patients.
What is Liraglutide used for?
A GLP-1 medication that mimics a natural gut hormone (97% similar to native GLP-1) and is the predecessor to semaglutide. FDA-approved for both type 2 diabetes (Victoza) and obesity (Saxenda). One of the most prescribed weight loss medications worldwide, with extensive long-term safety data including reduced risk of heart attack and stroke in diabetic patients.
What is the dosage for Liraglutide?
Diabetes (Victoza): 0.6 mg subcutaneous once daily for 1 week, then 1.2-1.8 mg once daily. Weight loss (Saxenda): 0.6 mg subcutaneous once daily, titrating by 0.6 mg weekly to target dose of 3.0 mg once daily. Injected once daily at any time, with or without food.
What are the side effects of Liraglutide?
Common: nausea (40%+ initially, typically resolves within 2-4 weeks), vomiting, diarrhea, constipation, injection site reactions, headache. Serious: pancreatitis, gallbladder disease including gallstones, acute kidney injury from dehydration, thyroid C-cell tumors (boxed warning based on rodent studies). Rare: anaphylaxis, angioedema, medullary thyroid carcinoma (theoretical). Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.
How does Liraglutide work?
Liraglutide is a GLP-1 receptor agonist with 97% amino acid homology to native human GLP-1(7-37), modified by a single amino acid substitution (Lys34Arg) and attachment of a C16 palmitoyl fatty acid chain to Lys26 via a glutamic acid spacer. This acylation is the key pharmacological modification — the C16 fatty acid chain non-covalently binds to serum albumin after injection, creating an albumin-bound depot that is slowly released, extending the half-life from 1-2 minutes (native GLP-1) to approximately 13 hours. The acylation also confers resistance to DPP-4 enzymatic degradation. Liraglutide activates the GLP-1 receptor (GLP-1R), a Gs-coupled GPCR expressed in pancreatic beta cells, the hypothalamus, the gastrointestinal tract, and the cardiovascular system. In pancreatic beta cells, GLP-1R activation increases intracellular cAMP, which enhances glucose-stimulated insulin secretion (GSIS) through PKA and Epac2 (exchange protein activated by cAMP) signaling. Crucially, this insulin secretion is glucose-dependent — it only occurs when blood glucose is elevated, which greatly reduces the risk of hypoglycemia compared to insulin or sulfonylureas. GLP-1R activation also suppresses glucagon secretion from alpha cells (reducing hepatic glucose output), promotes beta cell proliferation, and inhibits beta cell apoptosis. The weight loss mechanism operates primarily through hypothalamic GLP-1R activation. GLP-1 receptors in the arcuate nucleus and paraventricular nucleus reduce appetite by activating POMC/CART (anorexigenic) neurons and inhibiting NPY/AgRP (orexigenic) neurons. This produces a sustained reduction in hunger and food intake. In the GI tract, GLP-1R activation delays gastric emptying, prolonging postprandial satiety and slowing the rate of nutrient absorption. The combined effects on appetite reduction and gastric emptying produce clinically meaningful weight loss — approximately 5-8% of body weight in clinical trials at the 3.0 mg daily dose (Saxenda). The LEADER cardiovascular outcomes trial demonstrated that liraglutide also reduces major adverse cardiovascular events, likely through anti-inflammatory, anti-atherogenic, and cardioprotective effects of GLP-1R activation in vascular endothelium and cardiomyocytes.
How is Liraglutide administered?
Liraglutide is administered via subcutaneous injection (daily).
What is the half-life of Liraglutide?
The half-life of Liraglutide is 13 hours.
Is Liraglutide legal?
FDA approved: Victoza (2010, diabetes), Saxenda (2014, weight management). EMA approved. Widely available globally. Prescription required.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.